CLINICAL BASIS OF DIPYRIDAMOL USE IN OBSTETRIC PRACTICE
https://doi.org/10.17749/2313-7347.2017.11.2.045-048
Abstract
The currently accepted role of hemostatic disorders (antiphospholipid syndrome, genetic thrombophilia) in the pathogenesis of frequent obstetric complications (preeclampsia, premature placental abruption, feto-placental insufficiency, recurrent miscarriage) revolutionized the prevention and treatment of these pregnancy-associated abnormalities. An increasing number of direct and indirect anticoagulants have been introduced into clinical practice. The present review addresses the mechanisms of action of dipyridamole, an antiaggregant medication commonly used in obstetrics. In addition to its antiplatelet activity, dipyridamole is also known for other pharmacological effects, including the antioxidant and endothelioprotective activities.
About the Authors
S. V. AkinshinaRussian Federation
Akinshina Svetlana Vladimirovna - PhD, research associate, Department of Obstetrics and Gynecology, Faculty of Preventive Medicine
Address: ul. Trubetskaya, 8, str. 2, Moscow, Russia, 119991. ecology, Faculty of Preventive Medicine
V. O. Bitsadze
Russian Federation
Bitsadze Victoria Omarovna - MD, Professor, Department of Obstetrics and Gynecology, Faculty of Preventive Medicine
Address: ul. Trubetskaya, 8, str. 2, Moscow, Russia, 119991. ecology, Faculty of Preventive Medicine
A. D. Makatsariya
Russian Federation
Makatsariya Aleksandr Davidovich - MD, Professor, corresponding member of the Russian Academy of Sciences, Head of Department of Obstetrics and Gynecology, Faculty of Preventive Medicine
Address: ul. Trubetskaya, 8, str. 2, Moscow, Russia, 119991. ecology, Faculty of Preventive Medicine
References
1. Taddei S., Arzilli F., Arrighi P., Salvetti A. Dipyridamole decreases circulating renin- angiotensin system activity in hypertensive patients. Am J Hypertens. 1992; 5 (1): 29-31.
2. Ciacciarelli M., Zerbinati C., Violi F., Iuliano L. Dipyridamole: a drug with unrecognized antioxidant activity. Curr Top Med Chem. 2015; 15 (9): 822-9.
3. Iuliano L., Colavita A.R., Camastra C., Bello V., Quintarelli C., Alessandroni M., Piovella F., Violi F. Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole. Br J Pharmacol. 1996; 119 (7): 1438-46.
4. Massaro M., Scoditti E., Carluccio M.A., Calabriso N., Wabitsch M., Storelli C. et al. Dipyridamole decreases inflammatory metalloproteinase-9 expression and release by human monocytes. Thromb Haemost. 2013; 109 (2): 280-9. DOI: 10.1160/TH12-05-0326.
5. Kam A., Razmovski-Naumovski V., Zhou X., Truong J., Chan K. Nucleoside Transport Inhibition by Dipyridamole Prevents Angiogenesis Impairment by Homocysteine and Adenosine. J Pharm Pharm Sci. 2015; 18 (5): 871-81.
6. Duley L., Henderson-Smart D.J., Meher S., King J.F. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007; 2: CD004659.
7. Kiryushchenkov P.A., Alexandrina O.S., Belousov D.M. The effectiveness of dipyridamole in the «uterine form» of the syndrome of habitual pregnancy loss. [Effektivnost' dipiridamola pri «matochnoj forme» sindroma privychnoj poteri beremennosti]. Vrach. 2010; 8: 15-7.
8. Dodd J.M., McLeod A., Windrim R.C., Kingdom J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev. 2013; 7: CD006780. DOI: 10.1002/14651858. CD006780.pub3.
9. Yarrington C.D., Valente A.M., Economy K.E. Cardiovascular Management in Pregnancy: Antithrombotic Agents and Antiplatelet Agents. Circulation. 2015; 132 (14): 1354-64.
Review
For citations:
Akinshina S.V., Bitsadze V.O., Makatsariya A.D. CLINICAL BASIS OF DIPYRIDAMOL USE IN OBSTETRIC PRACTICE. Obstetrics, Gynecology and Reproduction. 2017;11(2):45-48. (In Russ.) https://doi.org/10.17749/2313-7347.2017.11.2.045-048

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.